Expression and survival significance of B-cell-specific Moloney murine leukemia virus integration site 1 and matrix metalloproteinase-9 in non-small-cell lung cancer

Mu,Mingkui; Song,Yang; Zhang,Bin

doi:10.3892/ol.2016.5209

Expression and survival significance of B-cell-specific Moloney murine leukemia virus integration site 1 and matrix metalloproteinase-9 in non-small-cell lung cancer

Authors:
- Mingkui Mu
- Yang Song
- Bin Zhang
View Affiliations

Affiliations: Institute of Hard Tissue Development and Regeneration, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China
Published online on: September 29, 2016 https://doi.org/10.3892/ol.2016.5209
Pages: 3715-3722
Copyright: © Mu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

One of the main challenges in lung cancer research is identifying patients at high risk of progression and metastasis following surgical resection. In the present study, the prognostic significance of B‑cell‑specific Moloney murine leukemia virus integration site 1 (BMI1) and matrix metalloproteinase-9 (MMP9) in non‑small‑cell lung cancer (NSCLC) was evaluated. BMI1 and MMP9 expression in tumors from 132 surgical NSCLC patients [squamous cell carcinoma (SCC), n=79; and adenocarcinoma (AD), n=53] was evaluated by immunohistochemistry. The clinical significance was determined using multivariate Cox regression analysis, Kaplan‑Meier curves and the log‑rank test. High BMI1 expression was more frequent in SCC compared with that in AD (P=0.015). Comparisons between the expression of BMI1 and that of other known biological markers revealed that the expression of BMI1 was correlated with that of MMP9 (χ2=4.241, P=0.039) in SCC. Although an association was not identified between high BMI1 expression and overall survival (OS) in NSCLC or AD, high BMI1 expression was an unfavorable predictor of survival in SCC according to the survival curves (P=0.038). In addition, combined high BMI1 and MMP9 expression levels were significantly correlated with SCC nodal/distant metastasis (χ2=6.392, P=0.014). Multivariate Cox proportional model analysis demonstrated that this combined marker was an independent prognostic indicator of OS in SCC (P=0.025; hazard ratio = 12.963; 95% confidence interval: 1.142‑7.637). Therefore, this study demonstrated that combined BMI1 and MMP9 expression may be used as a marker for the progression and metastasis of SCC. These results may aid in the elucidation of the potential mechanism underlying the involvement of BMI1 and MMP9 in tissue-specific SCC progression.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
2	Sy SM, Wong N, Lee TW, et al: Distinct patterns of genetic alterations in adenocarcinoma and squamous cell carcinoma of the lung. Eur J Cancer. 40:1082–1094. 2004. View Article : Google Scholar : PubMed/NCBI
3	Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP and Vansteenkiste J: International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 350:351–360. 2004. View Article : Google Scholar : PubMed/NCBI
4	Bruno A, Focaccetti C, Pagani A, et al: The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia. 15:133–142. 2013. View Article : Google Scholar : PubMed/NCBI
5	Scott WJ, Howington J, Feigenberg S, Movsas B and Pisters K: Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 Suppl. 3:234–242. 2007. View Article : Google Scholar
6	Haupt Y, Alexander WS, Barri G, Klinken SP and Adams JM: Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell. 65:753–763. 1991. View Article : Google Scholar : PubMed/NCBI
7	van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H and Berns A: Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell. 65:737–752. 1991. View Article : Google Scholar : PubMed/NCBI
8	van der Lugt NM, Domen J, Linders K, et al: Posterior transformation, neurological abnormalities and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev. 8:757–769. 1994. View Article : Google Scholar : PubMed/NCBI
9	Satijn DP and Otte AP: RING1 interacts with multiple polycomb-group proteins and displays tumorigenic activity. Mol Cell Biol. 19:57–68. 1999. View Article : Google Scholar : PubMed/NCBI
10	van Kemenade FJ, Raaphorst FM, Blokzijl T, et al: Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood. 97:3896–3901. 2001. View Article : Google Scholar : PubMed/NCBI
11	Kim JH, Yoon SY, Jeong SH, et al: Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast. 13:383–388. 2004. View Article : Google Scholar : PubMed/NCBI
12	Yonemitsu Y, Imazeki F, Chiba T, et al: Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma. Hum Pathol. 40:1304–1311. 2009. View Article : Google Scholar : PubMed/NCBI
13	Li W, Li Y, Tan Y, Ma K and Cui J: Bmi-1 is critical for the proliferation and invasiveness of gastric carcinoma cells. J Gastroenterol Hepatol. 25:568–575. 2010. View Article : Google Scholar : PubMed/NCBI
14	Li DW, Tang HM, Fan JW, et al: Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J Cancer Res Clin Oncol. 136:997–1006. 2010. View Article : Google Scholar : PubMed/NCBI
15	Chen H, Zhou L, Wan G, Dou T and Tian J: BMI1 promotes the progression of laryngeal squamous cell carcinoma. Oral Oncol. 47:472–481. 2011. View Article : Google Scholar : PubMed/NCBI
16	Tong YQ, Liu B, Zheng HY, et al: BMI-1 autoantibody as a new potential biomarker for cervical carcinoma. PLoS One. 6:e278042011. View Article : Google Scholar : PubMed/NCBI
17	Choy B, Bandla S, Xia Y, et al: Clinicopathologic characteristics of high expression of Bmi-1 in esophageal adenocarcinoma and squamous cell carcinoma. BMC Gastroenterol. 12:1462012. View Article : Google Scholar : PubMed/NCBI
18	Xin T, Zhang FB, Sui GJ and Jin XM: Bmi-1 siRNA inhibited ovarian cancer cell line growth and decreased telomerase activity. Br J Biomed Sci. 69:62–66. 2012.PubMed/NCBI
19	Vonlanthen S, Heighway J, Altermatt HJ, et al: The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer. 84:1372–1376. 2001. View Article : Google Scholar : PubMed/NCBI
20	Breuer RH, Snijders PJ, Smit EF, et al: Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia. 6:736–743. 2004. View Article : Google Scholar : PubMed/NCBI
21	Breuer RH, Snijders PJ, Sutedja GT, et al: Expression of the p16 (INK4a) gene product, methylation of the p16 (INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer. 48:299–306. 2005. View Article : Google Scholar : PubMed/NCBI
22	Vrzalikova K, Skarda J, Ehrmann J, et al: Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J Cancer Res Clin Oncol. 134:1037–1042. 2008. View Article : Google Scholar : PubMed/NCBI
23	Zhang XY, Dong QG, Huang JS, et al: The expression of stem cell-related indicators as a prognostic factor in human lung adenocarcinoma. J Surg Oncol. 102:856–862. 2010. View Article : Google Scholar : PubMed/NCBI
24	Lee MO, Lee HJ, Kim MA, et al: p16Ink4a suppression of lung adenocarcinoma by Bmi-1 in the presence of p38 activation. J Thorac Oncol. 6:423–431. 2011. View Article : Google Scholar : PubMed/NCBI
25	Hu J, Liu YL, Piao SL, Yang DD, Yang YM and Cai L: Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer. Lung Cancer. 77:593–599. 2012. View Article : Google Scholar : PubMed/NCBI
26	Huang J, Qiu Y, Chen G, Huang L and He J: The relationship between Bmi-1 and the epithelial-mesenchymal transition in lung squamous cell carcinoma. Med Oncol. 29:1606–1613. 2012. View Article : Google Scholar : PubMed/NCBI
27	Meng X, Wang Y, Zheng X, et al: shRNA-mediated knockdown of Bmi-1 inhibit lung adenocarcinoma cell migration and metastasis. Lung Cancer. 77:24–30. 2012. View Article : Google Scholar : PubMed/NCBI
28	Zhang X, Sun J, Wang H, et al: IGF-1R and Bmi-1 expressions in lung adenocarcinoma and their clinicopathologic and prognostic significance. Tumour Biol. 35:739–745. 2014. View Article : Google Scholar : PubMed/NCBI
29	Hiratsuka S, Nakamura K, Iwai S, et al: MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell. 2:289–300. 2002. View Article : Google Scholar : PubMed/NCBI
30	Mihaylova Z, Ludovini V, Gregorg V, et al: Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients. J BUON. 12:105–111. 2007.PubMed/NCBI
31	Jiang L, Wu J, Yang Y, et al: Bmi-1 promotes the aggressiveness of glioma via activating the NF-kappaB/MMP-9 signaling pathway. BMC Cancer. 12:4062012. View Article : Google Scholar : PubMed/NCBI
32	Li X, Yang Z, Song W, et al: Overexpression of Bmi-1 contributes to the invasion and metastasis of hepatocellular carcinoma by increasing the expression of matrix metalloproteinase (MMP)2, MMP-9 and vascular endothelial growth factor via the PTEN/PI3K/Akt pathway. Int J Oncol. 43:793–802. 2013.PubMed/NCBI
33	Wagenaar SS: New WHO-classification of lung and pleural tumors. Ned Tijdschr Geneeskd. 143:984–990. 1999.(In Dutch). PubMed/NCBI
34	Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 6:1471–1474. 2010. View Article : Google Scholar
35	Noguchi M: Stepwise progression of pulmonary adenocarcinoma-clinical and molecular implications. Cancer Metastasis Rev. 29:15–21. 2010. View Article : Google Scholar : PubMed/NCBI
36	Hayes DN, Monti S, Parmigiani G, et al: Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol. 24:5079–5090. 2006. View Article : Google Scholar : PubMed/NCBI
37	Silva J, García JM, Peña C, et al: Implication of polycomb members Bmi-1, Mel-18 and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT and c-Myc expression in primary breast carcinomas. Clin Cancer Res. 12:6929–6936. 2006. View Article : Google Scholar : PubMed/NCBI
38	He S, Iwashita T, Buchstaller J, Molofsky AV, Thomas D and Morrison SJ: Bmi-1 over-expression in neural stem/progenitor cells increases proliferation and neurogenesis in culture but has little effect on these functions in vivo. Dev Biol. 328:257–272. 2009. View Article : Google Scholar : PubMed/NCBI
39	Lindström MS, Klangby U and Wiman KG: p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene. 20:2171–2177. 2001. View Article : Google Scholar : PubMed/NCBI
40	Song LB, Li J, Liao WT, et al: The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest. 119:3626–3636. 2009. View Article : Google Scholar : PubMed/NCBI
41	Stetler-Stevenson WG: Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 103:1237–1241. 1999. View Article : Google Scholar : PubMed/NCBI
42	Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI
43	Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequeiros G and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer. 83:1153–1162. 1998. View Article : Google Scholar : PubMed/NCBI
44	Wang L, Wang Q, Li HL and Han LY: Expression of MiR200a, miR93, metastasis-related gene RECK and MMP2/MMP9 in human cervical carcinoma - relationship with prognosis. Asian Pac J Cancer Prev. 14:2113–2118. 2013. View Article : Google Scholar : PubMed/NCBI
45	Bergers G, Brekken R, McMahon G, et al: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2:737–744. 2000. View Article : Google Scholar : PubMed/NCBI